← back to the index
RX-009 opioid analgesic 2010

Darvon and Darvocet (propoxyphene) — the “Weak Opioid” That Poisoned Hearts, Banned in 2010

cardiac-arrhythmiaoverdose-mortalityqt-prolongationcardiologypain-managementtoxicology1960s2010s
Patients exposed
~10M U.S. users at withdrawal; tens of millions over its lifetime
Documented harm
Thousands of overdose deaths over decades; Florida propoxyphene deaths fell ~84% post-withdrawal
On market
1957→2010 (~53 years)
Status
Withdrawn

Summary

When the U.S. Food and Drug Administration asked manufacturers to pull propoxyphene from the American market on 19 November 2010, it was retiring a painkiller that Eli Lilly had introduced in 1957 and that had been prescribed to tens of millions of people across two regulatory generations; the documented record shows the agency acted only after a study it had itself ordered proved the harm, and decades after the first petition to ban the drug was filed. Propoxyphene — marketed alone as Darvon and combined with acetaminophen as Darvocet — was promoted for half a century as a mild, well-tolerated opioid for moderate pain. The gap between that gentle reputation and the molecule's actual pharmacology was the whole story: at or near ordinary therapeutic doses the drug prolonged the PR interval, widened the QRS complex, and lengthened the QT interval, the electrocardiographic signature of a compound that can stop a heart.

The harm was not subtle and not new. Propoxyphene blocks cardiac sodium channels more potently than the antiarrhythmic agents lidocaine, quinidine, and procainamide, and its long-lived metabolite norpropoxyphene accumulates — especially in the elderly and in patients with impaired kidneys — pushing toxic effects past the point of reversal. The consumer group Public Citizen petitioned the FDA to ban propoxyphene in 1978 and again in February 2006. The drug had been associated with more than 2,000 accidental U.S. deaths since 1981 and ranked among the most common drugs found in fatal overdoses, a mortality profile that prompted the United Kingdom to begin withdrawing the equivalent product, co-proxamol, in January 2005.

The verdict here is therefore plain at the outset: an approved, familiar, "weak" medicine reached enormous populations while the evidence that would eventually condemn it — sodium-channel data, autopsy series, decades of overdose statistics, and a foreign regulator's reversal — sat fully legible in the literature. The thing that finally moved the FDA was not new theory but a single dedicated experiment: a controlled electrocardiographic study in healthy volunteers, completed in 2010, showing that even at labeled doses propoxyphene measurably deranged cardiac conduction.

What followed the withdrawal was less a courtroom reckoning than a public-health correction visible in the morgue. In the state of Florida, where overdose deaths are tracked closely, fatalities involving propoxyphene fell on the order of 84 percent after the drug left the market — a natural experiment that quantified, in lives, the cost of every year the agency had waited. Propoxyphene became the standard byword for regulatory delay: a case in which the question was not whether a drug was dangerous but how long an agency could decline to answer a petition it had already received twice.

Timeline

1957
Darvon launched
Eli Lilly and Company introduces propoxyphene in the United States as a mild opioid analgesic for moderate pain; the combination with acetaminophen, Darvocet, follows and becomes one of the most widely prescribed pain products in the country.
1978
First petition to ban
The Health Research Group of Public Citizen petitions the FDA to remove propoxyphene from the market, citing overdose mortality and weak analgesic benefit. The agency does not ban the drug.
1981→
Overdose toll accumulates
Propoxyphene becomes associated with more than 2,000 accidental U.S. deaths over the following years; federal Drug Abuse Warning Network data tie a meaningful share of drug-related deaths to the compound.
2004
Peak prescribing
Roughly 23 million propoxyphene prescriptions are filled in the United States, making it the 12th most commonly prescribed generic drug; an estimated 10 million Americans are using it.
2005-01
United Kingdom acts first
Following an MHRA/Committee on Safety of Medicines review, the UK announces a phased withdrawal of co-proxamol over concerns about overdose lethality and a poor benefit profile, completed by the end of 2007.
2006-02
Public Citizen petitions again
Citing the UK reversal and the unchanged cardiac and overdose evidence, Public Citizen files a second petition to ban propoxyphene. The FDA again declines to remove the drug.
2009-01
FDA advisory committee votes to ban
A joint FDA advisory committee votes 14 to 12 that propoxyphene's risks outweigh its benefits and recommends withdrawal. The FDA does not immediately follow the recommendation.
2009-07
Stronger warnings, not removal
The FDA instead orders a boxed warning on overdose risk and directs the manufacturer, Xanodyne Pharmaceuticals, to conduct a dedicated cardiac (thorough QT) study.
2010
The ECG study returns
The FDA-mandated study in healthy volunteers shows that at therapeutic doses propoxyphene prolongs the PR interval, widens the QRS complex, and lengthens the QT interval — direct evidence of dose-independent conduction toxicity.
2010-11-19
Withdrawal requested and accepted
The FDA recommends against all continued use of propoxyphene; Xanodyne agrees to withdraw Darvon and Darvocet, and the agency asks generic manufacturers to follow.
2011-2017
Mortality drops where measured
In Florida, deaths involving propoxyphene fall by roughly 84 percent after withdrawal, confirming the drug as a major preventable contributor to overdose mortality.
2014-03-10
Approvals formally withdrawn
The Federal Register records the withdrawal of approval of 8 NDAs and 46 ANDAs for propoxyphene products, closing the regulatory file.

The Mild-Opioid Franchise: How a Weak Analgesic Reached Everyone

Propoxyphene was built and sold on the premise of mildness. Introduced by Eli Lilly in 1957, it was positioned as a step above non-opioid pain relievers but below the strong narcotics — potent enough to prescribe freely, weak enough to seem safe. That reputation, combined with the convenience of the acetaminophen combination Darvocet, made it one of the most prescribed pain products in the United States for decades; at its 2004 peak some 23 million prescriptions a year were written and roughly 10 million Americans were taking it. The trouble was that the analgesic benefit was modest and contested — multiple reviews found propoxyphene barely outperformed plain acetaminophen — while the pharmacology beneath the "weak opioid" label was anything but mild. Propoxyphene and its principal metabolite, norpropoxyphene, are powerful blockers of the cardiac sodium channel, more potent in that action than lidocaine, quinidine, or procainamide. The drug's reputation described its opioid effect; it said nothing about its electrophysiology, and prescribing was governed almost entirely by the reputation.

The Petitions Nobody Answered: Thirty Years of a Visible Signal

The case against propoxyphene did not emerge late; it was lodged formally in 1978, when Public Citizen first petitioned the FDA to ban it, and renewed in February 2006. Between those filings the drug was implicated in more than 2,000 accidental U.S. deaths after 1981 and turned up repeatedly in fatal-overdose statistics, with alcohol shown to potentiate its lethality and norpropoxyphene accumulating dangerously in the elderly and the renally impaired. By January 2005 a foreign regulator had drawn the obvious conclusion: the UK's CSM, citing overdose deaths and weak benefit, began phasing out co-proxamol, an action later credited with preventing several hundred self-poisoning deaths a year. The FDA, presented with the same evidence and a second petition, declined to remove the drug. In January 2009 its own advisory committee voted 14 to 12 that the risks outweighed the benefits and recommended withdrawal — and still the agency stopped short, ordering instead a boxed warning in July 2009 and directing Xanodyne to run a definitive cardiac study. For more than three decades the signal was legible and the institutional response was to ask for more proof of a conclusion it had been handed repeatedly.

The Study It Could Not Argue With: Conduction Toxicity at Labeled Doses

The withdrawal came only when the FDA's own experiment removed every remaining alibi. The thorough-QT study the agency had mandated tested propoxyphene at therapeutic doses in healthy volunteers and found unambiguous conduction toxicity: a prolonged PR interval, a widened QRS complex, and a lengthened QT interval — the trio of changes that mark a drug capable of triggering fatal arrhythmia. Crucially, the effect appeared at or only slightly above ordinary doses, which meant the danger was not confined to overdose or misuse; it was inherent to the molecule taken as directed. On 19 November 2010 the FDA recommended against all continued use of propoxyphene, Xanodyne agreed to withdraw Darvon and Darvocet, and the agency asked generic makers to follow. The reckoning that followed was epidemiological rather than judicial. In Florida, where medical examiners track overdose deaths in detail, fatalities involving propoxyphene fell by roughly 84 percent after the drug disappeared — a clean natural experiment converting the prior decades of inaction into a measurable, preventable body count. The "mild" painkiller had been, by its own electrocardiograms, a cardiac toxin all along.

Contributing Factors

01
A reputation that outran the pharmacology
Propoxyphene was governed by its "weak opioid" image, which described its analgesic effect and concealed its electrophysiology. Beneath the label it blocked cardiac sodium channels more potently than several antiarrhythmic drugs, yet prescribing tracked the reputation, not the mechanism. When a product's perceived safety rests on a category word rather than on its measured action, the most dangerous property can stay invisible for decades.
02
A long-lived metabolite that turned therapy into accumulation
Norpropoxyphene, propoxyphene's major metabolite, is itself cardiotoxic and accumulates with repeated dosing, especially in the elderly and in patients with reduced kidney function. A drug that clears slowly converts a "therapeutic dose" into a rising body burden over time, so harm scales with the very chronic use the product invited. Pharmacokinetics, not just acute dose, defined the hazard.
03
Petitions treated as opinions rather than evidence
Public Citizen petitioned for a ban in 1978 and again in 2006, and a foreign regulator acted in 2005, yet the FDA repeatedly declined. An agency that responds to external safety petitions by deferral — asking for more proof of a conclusion already supported — converts citizen oversight into a formality and absorbs years of additional exposure as the cost of its own inertia.
04
Warnings substituted for withdrawal
Even after its own advisory committee voted 14–12 to ban the drug in January 2009, the FDA chose a boxed warning and a study order over removal. A label change leaves a dangerous product on the market and shifts the burden of safety onto prescribers and patients; counting the deaths during each interval between warning and withdrawal measures the true price of the softer option.
05
Confirmation deferred to a study only the regulator could compel
The conduction toxicity that finally forced action was demonstrable years earlier in principle, but the decisive proof required a dedicated thorough-QT trial — which the agency did not mandate until 2009. When the one experiment that ends the debate is the regulator's to order, every year it postpones ordering it is a year of avoidable harm chosen by default.

Aftermath

The material consequence of the 19 November 2010 withdrawal was the disappearance of one of the most widely prescribed pain products in American history; roughly 10 million users had to be transitioned to other analgesics, and in March 2014 the Federal Register formally withdrew approval of 8 NDAs and 46 ANDAs, closing the file. The durable ripple was epidemiological and unusually legible: in Florida, propoxyphene-involved deaths fell by approximately 84 percent, a natural experiment that retroactively priced every year of delay in lives. The episode hardened a regulatory expectation — that "weak" or long-established opioids are not exempt from dedicated cardiac-safety testing — and it became a reference point in the broader reckoning over how slowly the FDA acts on accumulating mortality signals, a critique that would echo through the opioid era that followed. What remains is a cautionary name. "Propoxyphene" is now invoked whenever a familiar, mild-seeming, long-grandfathered medicine is found to have carried an intrinsic, measurable, fatal toxicity that regulators were petitioned to address decades before they did — the canonical case of a drug condemned not by new science but by an agency finally consenting to run the test.

Lessons

  1. Distrust the safety implied by a category word: when a product's reputation rests on a label like "mild" or "weak," demand the direct mechanistic measurement — here a thorough-QT study — before trusting the reputation, because the word describes the intended effect, not the lethal one.
  2. Weigh a long-lived toxic metabolite as heavily as the parent drug; if a compound accumulates with chronic use, a "therapeutic dose" is a rising body burden, and the patients who take it most faithfully — the elderly, the renally impaired — bear the greatest risk.
  3. Read a citizen petition or a foreign regulator's withdrawal as evidence, not as opinion to be deferred: when an outside party has already reached the conclusion on the same data, the burden should shift to defending continued sale, not to demanding still more proof.
  4. Treat a boxed warning as the floor of a response, never the ceiling: if a signal is strong enough to change the label, ask why it is not strong enough to remove the product, and count the deaths accumulating during every interval of delay.
  5. When the decisive experiment is yours to order, order it early: a regulator that postpones the one study that would settle a safety question is choosing the harm that occurs while it waits.

References